Calidi Biotherapeutics Inc Ordinary Shares CLDI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.12
- Day Range
- $0.12–0.13
- 52-Week Range
- $0.11–10.92
- Bid/Ask
- $0.12 / $0.12
- Shares Outstanding
- 19.31M
- Market Cap
- $2.37M
- Volume/Avg
- 149,134 / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 29
- Website
- https://www.calidibio.com
Valuation
|
Metric
|
CLDI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.29 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CLDI
Financial Strength
|
Metric
|
CLDI
|
|---|---|
Quick Ratio | 1.73 |
Current Ratio | 1.92 |
Interest Coverage | −109.36 |
Quick Ratio
CLDI
Profitability
|
Metric
|
CLDI
|
|---|---|
Return on Assets (Normalized) | −157.71% |
Return on Equity (Normalized) | −368.99% |
Return on Invested Capital (Normalized) | −211.44% |
Return on Assets
CLDI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!@dJz$ | LOCK|>y!#H | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!^@<?xf | LOCK|psGj! | $70B | |||
| argenx SE ADR
ARGX
| LOCK|Lqd<c<! | LOCK|x! | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&yzVNn | LOCK|!^mSF | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$Gqm#z | LOCK|N#! | $37B | |||
| Moderna Inc
MRNA
| LOCK|L#Q$@#! | LOCK|&% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!>wn?>&S | LOCK|khM! | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&ZSDLM | LOCK|TR | $23B | |||
| Incyte Corp
INCY
| LOCK|<w<p^J! | LOCK|L^M | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|>@zSp> | LOCK|^$k | $16B |
United States